

# Giuseppe Patti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4983192/giuseppe-patti-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152 papers	6,611 citations	37 h-index	80 g-index
171 ext. papers	8,219 ext. citations	4.9 avg, IF	5.55 L-index

#	Paper	IF	Citations
152	Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multi-center study.. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2022</b> ,	4.6	0
151	Reduction of admissions for urgent and elective pacemaker implant during the COVID-19 outbreak in Northern Italy. <i>Journal of Cardiovascular Medicine</i> , <b>2022</b> , 23, 22-27	1.9	1
150	The Incidence and Impact of In-Hospital Bleeding in Patients with Acute Coronary Syndrome during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2926	5.1	1
149	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 345, 7-13	3.2	13
148	Prevention of ischaemic events in subjects with polydistrict vascular disease. <i>European Heart Journal Supplements</i> , <b>2021</b> , 23, E103-E108	1.5	0
147	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , <b>2021</b> , 144, 1323-1343	16.7	9
146	Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 782-790	5.1	6
145	Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	1
144	Role of Osteopontin as a Potential Biomarker of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Other Connective Tissue Diseases (CTDs). <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	4
143	Speckle tracking echocardiography in primary mitral regurgitation: should we reconsider the time for intervention?. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	3
142	How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 924-928	1.9	0
141	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13562	4.6	2
140	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , <b>2021</b> , 2021, 8863053	3.2	9
139	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2187-2199	15.1	9
138	Usefulness of a multiparametric evaluation including global longitudinal strain for an early diagnosis of acute myocarditis. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 3203-3211	2.5	
137	Family history in first degree relatives of patients with premature cardiovascular disease. <i>International Journal of Cardiology</i> , <b>2021</b> , 333, 215-218	3.2	
136	Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 235-237	3.2	2

135	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e006852	5.8	3
134	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 639970	4.9	9
133	Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 746-753	5.1	1
132	Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 227-234	4.2	8
131	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , <b>2021</b> , 2021, 5556207	3.7	2
130	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 379-387	3.7	13
129	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 591-599	3.7	3
128	Catheterization laboratory activity before and during COVID-19 spread: A comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE). <i>International Journal of Cardiology</i> , <b>2021</b> , 323, 288-291	3.2	8
127	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1054-1065	7	45
126	Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2036142	10.4	132
125	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. <i>Lancet, The</i> , <b>2021</b> , 397, 199-207	4.0	32
124	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1583-1591	3.7	5
123	Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e009375	6.4	9
122	Speckle Tracking Echocardiography: Early Predictor of Diagnosis and Prognosis in Coronary Artery Disease. <i>BioMed Research International</i> , <b>2021</b> , 2021, 6685378	3	7
121	Two and Three-Dimensional Echocardiography in Primary Mitral Regurgitation: Practical Hints to Optimize the Surgical Planning. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 706165	5.4	1
120	Left atrial conduit flow rate at baseline and during exercise: an index of impaired relaxation in HFpEF patients. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4334-4342	3.7	4
119	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 140, 111783	7.5	
118	Management of patients explanted for implantable cardioverter defibrillator infections: Bridge therapy with external temporary ICD. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2021</b> , 44, 1884-1889	1.6	0

117	Unexpected Pulmonary Embolism Late After Recovery from Mild COVID-19?. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2021</b> , 8, 002854	1.2	1
116	New echocardiographic indices of shift to biventricular failure to optimize risk stratification of chronic heart failure. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	2
115	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , <b>2020</b> , 20, 559-570	4	5
114	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , <b>2020</b> , 318, 67-73	3.2	4
113	Subclinical atrial fibrillation: when to give NAO?. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, E105-E109	0	0
112	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1093-1104	3.7	2
111	Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 88-89	59.2	582
110	Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	14
109	Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 77, 11-21	3.1	0
108	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> ,	6.4	2
107	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , <b>2020</b> , 41, 2083-2088	9.5	437
106	Primum non nocere does not justify clinical inertia for stroke prevention in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 71, 11-12	3.9	
105	Contributors to survival benefit of dual versus single antithrombotic therapy in chronic coronary syndrome: Survival benefit of dual antithrombotic therapy in CCS. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 72, 97-98	3.9	1
104	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 751-758	3.758	4
103	Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 314-321	7	18
102	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , <b>2020</b> , 71, 235-241	2.1	2
101	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. <i>American Journal of Cardiology</i> , <b>2020</b> , 134, 83-90	3	5
100	Early risk of mortality, cardiovascular events, and bleeding in patients with newly diagnosed atrial fibrillation. <i>European Heart Journal Supplements</i> , <b>2020</b> , 22, L110-L113	1.5	0

99	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. <i>Scientific Reports</i> , <b>2020</b> , 10, 20731	4.9	42
98	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 1899-1913	4.5	84
97	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , <b>2020</b> , 113, 642-651	2.7	3
96	Outcomes of acute coronary syndromes in coronavirus disease 2019. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1601-1604	6.1	5
95	Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 4182	3.7	14
94	SARS-CoV-2 infection: diagnostic testing results occasionally require special attention. <i>Emerging Microbes and Infections</i> , <b>2020</b> , 9, 1955-1957	18.9	1
93	Change over time of COVID-19 hospital presentation in Northern Italy. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 81, 100-103	3.9	5
92	Infective endocarditis complicating COVID-19 pneumonia: a case report. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-5	0.9	6
91	The Role of Clopidogrel in 2020: A Reappraisal. <i>Cardiovascular Therapeutics</i> , <b>2020</b> , 2020, 8703627	3.3	24
90	COVID-19 and Acute Coronary Syndromes: Current Data and Future Implications. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 593496	5.4	11
89	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1662-1668	3	15
88	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1773-1784	7	11
87	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 749-757.e5	2.4	34
86	Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy after Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 627-635	3	11
85	Percutaneous Left Atrial Appendage Closure: Acute Effects on Left Atrial Pressure in Humans. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1089-1091	5	1
84	De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 1-10	5.1	18
83	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , <b>2019</b> , 9, e022478	3	29
82	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2019</b> , 35, e3145	7.5	4

81	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , <b>2019</b> , 70, 257-263	2.1	10
80	CHADSVASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1987-1997	3.9	12
79	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219676	3.7	7
78	Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 191-203	3.3	1
77	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , <b>2019</b> , 286, 198-207	3.2	13
76	Long-Term Prognosis and Outcome Predictors in Takotsubo Syndrome: A Systematic Review and Meta-Regression Study. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 143-154	7.9	40
75	Intracardiac echocardiography with ultrasound probe placed in the upper left pulmonary vein to guide left atrial appendage closure: First description. <i>Catheterization and Cardiovascular Interventions</i> , <b>2019</b> , 93, 169-173	2.7	4
74	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , <b>2019</b> , 16, 113-130	14.8	37
73	Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 718-724	3	35
72	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , <b>2018</b> , 265, 141-147	3.2	26
71	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 1019-1028	3.7	1
70	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , <b>2018</b> , 69, 795-802	2.1	25
69	Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: The LAAO Italian Multicenter Registry. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1086-1092	5	27
68	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , <b>2018</b> , 265, 118-124	3.2	13
67	Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials. <i>International Journal of Cardiology</i> , <b>2018</b> , 266, 75-80	3.2	4
66	Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. <i>Anatolian Journal of Cardiology</i> , <b>2018</b> , 19, 67-71	0.8	17
65	Author's Reply. <i>Anatolian Journal of Cardiology</i> , <b>2018</b> , 19, 292	0.8	
64	Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation. <i>Monaldi Archives for Chest Disease</i> , <b>2018</b> , 88, 958	2.7	4



63	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , <b>2018</b> , 18, 138	5.6	3
62	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 936-943	3	10
61	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 160-166	3.2	15
60	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 409-419	15.1	46
59	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 41, e10-e11	3.9	1
58	Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2017</b> , 33, e2876	7.5	38
57	Intradivice misalignment predicts residual leak in patients undergoing left atrial appendage closure. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 900-907	1.9	2
56	Left atrial appendage closure using AMPLATZER devices: A large, multicenter, Italian registry. <i>International Journal of Cardiology</i> , <b>2017</b> , 248, 103-107	3.2	37
55	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-european egistry in trial ibrillation). <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	93
54	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186961	3.7	15
53	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , <b>2017</b> , 38, 877-887	9.5	41
52	Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials. <i>American Heart Journal</i> , <b>2016</b> , 176, 36-43	4.9	7
51	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 165-71	3	21
50	Safety and Efficacy of Switching From Clopidogrel to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: A Study-level Meta-analysis From 15 Studies. <i>Journal of Cardiovascular Pharmacology</i> , <b>2016</b> , 67, 336-43	3.1	3
49	Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". <i>Heart Rhythm</i> , <b>2015</b> , 12, 2515-20	6.7	4
48	Meta-analysis compares anticoagulant strategies in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Evidence-Based Medicine</i> , <b>2015</b> , 20, 65		0
47	Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 837-43	3	25
46	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2015</b> , 36, 1762-71	9.5	218

45	Comparison among patients $\geq 75$ years having percutaneous coronary angioplasty using drug-eluting stents versus bare metal stents. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1179-84	3	7
44	Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 395-6	3.7	
43	Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score. <i>Circulation: Cardiovascular Interventions</i> , <b>2015</b> , 8,	6	7
42	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A State-of-the-art Paper. <i>European Heart Journal</i> , <b>2014</b> , 35, 2213-23b	9.5	55
41	Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. <i>International Journal of Cardiology</i> , <b>2014</b> , 177, 219-28	3.2	29
40	Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 1124-9	3	26
39	Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , <b>2014</b> , 174, 440-1	3.2	4
38	Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. <i>Circulation Journal</i> , <b>2014</b> , 78, 33-41	2.9	18
37	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. <i>Platelets</i> , <b>2014</b> , 25, 348-56	3.6	16
36	Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. <i>Journal of Cardiovascular Translational Research</i> , <b>2013</b> , 6, 346-54	3.3	2
35	Percutaneous closure of a pulmonary arteriovenous malformation in young patient with cryptogenic stroke. <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, e26-7	5	4
34	Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). <i>American Journal of Cardiology</i> , <b>2013</b> ,	3	13
33	Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) study. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1379-87	15.1	48
32	Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 1413-8	3	14
31	Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study). <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 1739-44	3	21
30	The protective effect of clopidogrel and atorvastatin in patients undergoing carotid stenting. <i>Interventional Cardiology</i> , <b>2013</b> , 5, 371-373	3	
29	Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). <i>American Journal of Cardiology</i> , <b>2013</b> , 110, 173-84	3	47
28	Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study. <i>International Journal of Cardiology</i> , <b>2012</b> , 160, 213-4	3.2	3



27	A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. <i>JACC: Cardiovascular Interventions</i> , <b>2012</b> , 5, 281-9	5	69
26	Platelet function and inhibition in ischemic heart disease. <i>Current Cardiology Reports</i> , <b>2012</b> , 14, 457-67	4.2	8
25	High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 771-8	15.1	75
24	Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 771-8	15.1	97
23	Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1945-54	15.1	339
22	Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1-7	3	83
21	Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1-7	3	157
20	Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. <i>Circulation</i> , <b>2011</b> , 123, 1622-32	16.7	131
19	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. <i>American Journal of Cardiovascular Disease</i> , <b>2011</b> , 1, 255-63	0.9	1
18	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>European Heart Journal</i> , <b>2010</b> , 31, 1337-43	9.5	33
17	Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 550-7	15.1	86
16	Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. <i>Catheterization and Cardiovascular Interventions</i> , <b>2010</b> , 75, 128-34	2.7	5
15	Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2010</b> , 106, 619-23	3	65
14	Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2010</b> , 3, 318-23	5	50
13	Contemporary issues on clopidogrel therapy. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 201-11	3.7	1
12	Combining antiplatelet and anticoagulant therapies. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 95-109	15.1	121
11	Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage During Angioplasty) Randomized Trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 558-65	15.1	240
10	Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 279-85	3	112

9	Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 1328-34	3	26
8	Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. <i>Circulation</i> , <b>2008</b> , 118, 1122-33	15.1	312
7	Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1272-8	15.1	366
6	Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) study. <i>Circulation</i> , <b>2007</b> , 115, 1721-8	15.1	94
5	Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention: Results From the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) Substudy. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 1560-1566	15.1	83
4	Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. <i>Circulation</i> , <b>2005</b> , 111, 70-5	16.7	150
3	Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , <b>2005</b> , 111, 2099-106	16.7	552
2	Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. <i>Circulation</i> , <b>2004</b> , 110, 674-8	16.7	386
1	Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 372-6	3	50